Tanibayashi Masayuki, senior analyst with a Tokyo investment consultancy, compares biotech business to a marathon. The race has just started. We have come only five kilometers, and no one knows who will win in the end. Frontrunners may manage to keep their position. Then again latecomers might spurt ahead.
Tortoises can take heart.
All Rights Reserved. Terms under which this service is provided to you. Read our privacy guidelines .